Sirolimus for moderate lupus activity
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests whether sirolimus, a medication usually used to prevent organ transplant rejection, can help reduce lupus disease activity. If you have active lupus that isn't severe in your kidneys or brain, this could be a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed lupus diagnosis, with at least 4 of the 11 standard criteria for lupus.
- Your blood tests must show a positive ANA at a specific level (titer of 1:80 or higher).
- Your lupus medications must be stable for at least 30 days (or 90 days for belimumab) before starting.
- You must have moderate lupus activity that affects at least one organ system (excluding kidneys or brain) or two organ systems, based on a special scoring system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This study tests whether sirolimus (an immune-calming drug) is safe and helpful for people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. If you join, you'll get either sirolimus or a placebo alongside your usual treatment, to see if it reduces clotting problems.
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
This trial tests if sirolimus, a medicine that calms the immune system, can safely raise platelet counts in people with antiphospholipid antibodies and persistently low platelets. It may be an option if other treatments haven't worked or you want a simpler drug plan.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
Hear when a new Lupus Erythematosus, Systemic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.